Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis

Table 2 Breakdown of costs (€) by health state.

Cost components per cycle (6-months)	NESRD	ESRD First 2 cycles	ESRD Subsequent cycles	Terminal ESRD
moxonidine 0.3 mg/d^†	82.80	-	-	-
nitrendipine 20 mg/d^†	74.40	-	-	-
Other antihypertensives^†	93.90	-	-	-
Consultations, diagnostics, laboratory services, diuretics^‡	213.00	-	-	-
Dialysis including consultations, drugs, diagnostics and laboratory services*	-	34,522.00	32,627.00	-
Transplantation including consultations, drugs, diagnostics and laboratory services*	-	22,850.00	4,570.00	-
Terminal ESRD care^‡	-	-	-	1,416.00

† z-index: Cost of antihypertensives based on patient usage: 89% on ACE I (ddd enalapril 25 mg) and 11% on ARB (ddd losartan 50 mg), and 35.6% on beta blocker (ddd atenolol 75 mg) and 27.4% on alpha blocker (ddd doxazosin 4 mg). Costs of diuretics were assumed to be included in NESRD costs based on manuscript van Hout et al.
‡ van Hout et al
* de Wit et al

ISSN: 1471-2369